What is the current market size and future outlook for the cancer clinical decision tools market?
The cancer clinical decision tools market size has grown strongly in recent years. It will grow from $0.5 billion in 2024 to $0.55 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to the growing prevalence of cancer, increasing complexity of cancer treatment, rising demand for personalized medicine, growing adoption of value-based healthcare, increasing availability of cancer data, and government support for cancer research and development.
The cancer clinical decision tools market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to global aging population, patient engagement and shared decision-making, patient-centric care, clinical research and evidence-based medicine. Major trends in the forecast period include advancements in medical imaging, AI-driven clinical decision support, telemedicine and remote consultations, predictive analytics, interoperability and data standards, and ethical and regulatory considerations.
Get Your Free Sample of The Global Cancer Clinical Decision Tools Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3463&type=smp
How has the cancer clinical decision tools market evolved, and what factors have shaped its growth?
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer clinical decision tools market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates across the globe will increase the demand for cancer clinical decision tools to make treatment decisions faster, thereby contributing to the cancer clinical decision tools market growth.
What are the major segments of the cancer clinical decision tools market?
The cancer clinical decision tools market covered in this report is segmented –
1) By Type: Risk Assessment Tool(RAT), Qcancer
2) By End-User: Hospital, Clinics
Subsegments:
1) By Risk Assessment Tool (RAT): Family History Assessment, Genetic Testing and Counseling, Lifestyle and Environmental Risk Factors Evaluation
2) By Qcancer: Symptom Checker, Risk Calculator, Guideline-Based Recommendations
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Which companies dominate the cancer clinical decision tools market?
Major companies operating in the cancer clinical decision tools market include McKesson Corporation, Medical Information Technology Inc., Philips Healthcare, Siemens Healthineers AG, Elsevier B.V., Macmillan Publishers Limited, National Decision Support Company, Cerner Corporation, GE Healthcare, Allscripts Healthcare Solutions Inc., Epic Systems Corporation, RaySearch Laboratories AB, Elekta AB, Varian Medical Systems Inc., Accuray Incorporated, F. Hoffmann-La Roche Ltd., Flatiron Health Inc., Tempus Labs Inc., NantHealth Inc., Syapse Inc., Inspirata Inc., Oncora Medical Inc., Prognos Health Inc., Deep 6 AI Inc., PathAI Inc., Enlitic Inc., Ibex Medical Analytics Ltd., Zebra Medical Vision Ltd., Aidoc Medical Ltd.
How will industry trends affect the trajectory of the cancer clinical decision tools market?
Major companies operating in the cancer clinical decision tools market are exploring innovative products such as the BenchMark Ultra Plus tissue staining system to gain a competitive advantage. The BenchMark Ultra Plus system optimizes tissue staining for faster and more accurate pathology results. For instance, in June 2022, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, launched the BenchMark Ultra Plus tissue staining system, which boasts improved workflow efficiency, testing processes, and sustainability features. This innovative system empowers pathologists to deliver high-quality, time-sensitive results to medical professionals and patients. The BenchMark Ultra Plus system represents the next step in the BenchMark series’ evolution, automating previously manual slide-by-slide processes and revolutionizing cancer diagnostics.
How do regional factors impact the cancer clinical decision tools market, and which region is the largest contributor?
North America was the largest region in the cancer clinical decision tools market in 2024. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Cancer Clinical Decision Tools Market Report 2025 Offer?
The cancer clinical decision tools market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cancer clinical decision tools refer to the tools that are developed to help medical practitioners identify suspected cancer signs and symptoms and treat patients effectively. These tools aid in clinical decision-making by assisting GPs in deciding whether to refer or seek additional diagnostic testing in patients suspected of having cancer.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3463
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
